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Abstract
Background: In view of the high level of chloroquine resistance in many countries, WHO has
recommended the use of combination therapy with artemisinin derivatives in the treatment of
uncomplicated malaria due to Plasmodium falciparum. Four antimalarial drug combinations,
artesunate plus amodiaquine (Arsucam®), artesunate plus mefloquine (Artequin®), artemether plus
lumefantrine (Coartem®; four doses and six doses), and amodiaquine plus sulphadoxine-
pyrimethamine, were studied in five health districts in Senegal.
Methods: This is a descriptive, analytical, open, randomized study to evaluate the efficacy and
tolerability of these four antimalarial combinations in the treatment of uncomplicated falciparum
malaria using the 2002 WHO protocol.
Results: All drug combinations demonstrated good efficacy. On day 28, all combinations resulted
in an excellent clinical and parasitological response rate of 100% after correction for PCR results,
except for the four-dose artemether-lumefantrine regimen (96.4%). Follow-up of approximately
10% of each treatment group on day 42 demonstrated an efficacy of 100%.
The combinations were well tolerated clinically and biologically. No unexpected side-effect was
observed and all side-effects disappeared at the end of treatment. No serious side-effect requiring
premature termination of treatment was observed.
Conclusion: The four combinations are effective and well-tolerated.
Background
Approximately 35% of in-patient and out-patient clinic
attendance in Senegal are due to malaria [1]. Studies car-
ried out by staff of the Parasitology Laboratory, Faculté de
Médecine, Université Cheikh Anta Diop, Dakar, have
demonstrated high levels of resistance to chloroquine,
which was used as the first-line treatment of uncompli-
cated malaria and as chemoprophylaxis in pregnant
women [2,3]. Clinical failure rates higher than 25% have
been observed at more than half of the sites surveyed.
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The development and rapid increase of chloroquine resist-
ance in many countries led the World Health Organiza-
tion to organize a technical consultation in April 2001[4],
during which the association of two antimalarial drugs
was recommended for the treatment of uncomplicated
malaria, particularly those combining a classical antima-
larial with an artemisinin derivative; such combinations
are referred to as Artemisinin Combination Therapy
(ACT).
In this study, the efficacy, safety and tolerability of three
ACT for the treatment of malaria in Senegal were evalu-
ated : artesunate plus amodiaquine (Arsucam®), artesu-
nate plus mefloquine (Artequin®), and artemether plus
lumefantrine (Coartem®; four doses and six doses). As a
comparison, evaluation of combined therapy with amodi-
aquine plus sulphadoxine-pyrimethamine (SP) was also
done; these latter antimalarial drugs are readily available
in Senegal and were in use as a therapeutic strategy at the
time of the study.
The objectives of the study were to evaluate the clinical
and biological efficacy, safety and tolerability of these
combinations in the treatment of uncomplicated malaria
due to Plasmodium falciparum in Senegal, in order to gen-
erate data which could be used to determine the most
effective antimalarial treatment policy.
Methods
This descriptive, analytical, open, randomized study was
carried out to evaluate the following antimalarial combi-
nations in the treatment of P. falciparum uncomplicated
malaria: artesunate-mefloquine(Artequin®; Laboratoire
Mepha), artesunate-amodiaquine(Arsucam®; Laboratoire
Sanofi Aventis), artemether-lumefantrine(Coartem®; Lab-
oratoire Novartis), amodiaquine-SP (Pharmacie Nation-
ale d'Approvisionnement du Sénégal).
The study was carried out during the transmission periods
of 2002 and 2003 in five observation sites distributed
according to the epidemiology of malaria transmission in
Senegal: Richard Toll and Podor in the north, Guediawaye
and Kaolack in the central zone and Velingara in the
south. The transmission of malaria is moderate in these
different zones with a peak during the rainy season.
Study population
Patients were recruited from those presenting at the
healthcare centers with clinical signs suggestive of
malaria. After a thick peripheral blood smear for screen-
ing, patients of all ages who fulfilled the inclusion criteria
laid down by WHO/2002 [5] were selected to take part in
the study. The population size was determined according
to the following criteria: the proportion of probable clini-
cal failures with the antimalarial combinations studied
should not be higher than 10%, for a level of confidence
(P) of 95% and a precision (p) of 10%, taking into
account patients who were excluded or lost to follow-up.
Using these criteria, a minimum of 50 patients was
required in each treatment arm at each site. The inclusion
and exclusion criteria are described in the WHO/2002
protocol [5].
All patients gave their informed consent before participat-
ing in the study. The study protocol was approved by the
ethics committee of the Ministry of Health
Administration of antimalarial treatment
After inclusion, patients were weighed before being allo-
cated to a treatment arm. All medication was adminis-
tered under the direct supervision of a physician. If a
patient vomited immediately after a dose, the same dose
was re-administered within 30 minutes. Half of the dose
was given if vomiting continued after the first 30 min. In
the case of persistent vomiting, the patient was excluded
from the study and sent to the medical team at the health
center for management using the standard treatment in
current use.
Dosages of the study drugs were as follows:
(1) artesunate-mefloquine: for adults, 200 mg/day artesu-
nate plus 250 mg/day mefloquine, for 3 days; for children,
100 mg/day artesunate plus 125 mg/day mefloquine, for
3 days;
(2) artesunate-amodiaquine: 4 mg/kg/day artesunate plus
10 mg/kg/day amodiaquine, for 3 days. The dosages were
also adjusted according to the age of the patient;
(3) artemether-lumefantrine: two dosages were adminis-
tered: (i) in adults, four doses of four tablets repeated after
8, 24, 48 h; in children weighing 5–15 kg, one tablet
repeated at 8, 24 and 48 h; (ii) six doses consisting of two
daily doses for 3 days;
(4) amodiaquine-SP: 10 mg/kg/day amodiaquine for 3
days and half a tablet per 10 kg of SP as a single dose only
on the first day.
All side-effects were monitored actively and passively dur-
ing the study.
Clinical evaluation and biological tests
Clinical evaluation and blood sampling from finger pricks
for the preparation of thick peripheral blood smears were
carried out on days 0, 1, 2, 7, 14, 21 and 28; 30% of the
patients were also examined on day 42. Blood smears
were stained with Giemsa and 200 leukocytes were read.
Parasitaemia was expressed as the number of asexual par-Malaria Journal 2007, 6:80 http://www.malariajournal.com/content/6/1/80
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asites per microliter of blood according to the following
formula: number of asexual parasites × 8,000/200.
Twenty-five percent of the patients were selected ran-
domly and blood cell counts and levels of transaminases
(Alanine amino transferase, ALAT, and Aspartate amino
transferase, ASAT) and creatinine were determined on
days 0, 14 and 28 to determine hepatic and renal func-
tion.
Biological tolerability was assessed by measuring haemo-
globin (normal value: 12–17 g/dL), transaminases (ALAT
between 5–30 UI/L, ASAT between 5–35 UI/L), and creat-
ininaemia (normal value: 5–14 mg/L).
Blood collection on filter paper was carried out for all
patients on days 0 and 28, and on all other days in cases
of clinical or parasitological failure for genotyping the
strain of Plasmodium. Genotyping was carried out in the
Parasitology Laboratory, Faculté de Médecine, Université
Cheikh Anta Diop, Dakar.
Efficacy end-point criteria
The primary end-point criteria used to determine the effi-
cacy of treatment were absence of parasites and clinical
signs on days 14 and 28, and good clinical and biological
tolerability. The secondary end-point criteria were the
time taken for the parasites to disappear, and for gameto-
cyte clearance.
Definition of clinical and parasitological failure
The following definitions of clinical and parasitological
failure were used:
Early therapeutic failure
This was defined as a patient who presented with danger
signs between days 1 and 3, accompanied by parasitae-
mia; a patient with an axilliary temperature of > 37°C
accompanied by parasitaemia on day 3; parasitaemia on
day 3 > 25% that on day 0; and a patient with parasitae-
mia on day 2 higher than that on day 0.
Late therapeutic failure
This was defined as a patient presenting with danger signs
between days 3 and 28, accompanied by parasitaemia; or
a patient presenting with parasitaemia and a temperature
> 37.5°C between days 3, 14 and 28.
Parasitological failure
Parasitological failure was defined as a patient presenting
with parasites on day 28.
Overall therapeutic failure
This was defined as the sum of therapeutic failures plus
parasitological failures.
Adequate clinical and parasitological response (ACPR)
ACPR was defined as the absence of parasites and clinical
signs on day 28.
Patients who were considered to have failed clinically
were given second-line therapy with quinine at a dose of
25 mg/kg/day for 5 days. All patients were subjected to
clinical and biological tests during the 7 days following
the administration of second-line therapy.
Analysis of data
Data were collected and analysed using Epi info 6.
Descriptive statistics were used to compare the demo-
graphic characteristics of the study population and their
initial clinical and biological characteristics (temperature,
geometric mean parasitaemia, etc.).
Clinical and biological data were compared with a confi-
dence interval of 95%. All the clinical and laboratory data
collected were subjected to quality control. The study was
carried out according to standard operating procedures
following the guidelines of good clinical practice.
Results
Study population and allocation of treatment
A total of 955 patients who fulfilled the inclusion criteria
were included in the study. All patients gave their
informed consent before participating in the study. Treat-
ment was allocated as follows: 360 were given artesunate-
amodiaquine, 145 were treated with artesunate-meflo-
quine, 140 were given four doses of artemether-lumefan-
trine, 149 were given six doses of artemether-
lumefantrine, and 161 received amodiaquine-SP (Am-
SP).
A comparison of the demographic and laboratory data at
inclusion into the study showed that all treatments groups
were practically identical (Table 1).
Efficacy of treatment
On day 14, the ACPR was 100% for artesunate-amodi-
aquine, artesunate-mefloquine and Am-SP. For arte-
mether-lumefantrine given as four doses, one case of
clinical failure was observed resulting in an ACPR of
99.3% (Table 2). On day 14, the difference between this
drug combination and the others was not statistically sig-
nificant. On day 21, the percentage of clinical failures was
1.4% for artesunate-amodiaquine, 0.7% for artesunate-
mefloquine, 3.6% for artemether-lumefantrine (four
doses) and 0.6% for Am-SP. Once again, these differences
between the groups were not statistically significant. On
day 28, 16 cases of clinical failure and two cases of parasi-
tological failure (88.8%) were observed in the artemether-
lumefantrine (four-dose) group compared with 97.5%,
97.9% and 98.7% respectively for artesunate-amodi-Malaria Journal 2007, 6:80 http://www.malariajournal.com/content/6/1/80
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aquine, artesunate-mefloquine and Am-SP. At this time-
point, the difference between artemether-lumefantrine
and the other treatment groups was statistically signifi-
cant(p < 0.0001) (Table 3). There was no statistically sig-
nificant difference when the other combinations were
compared (artesunate-amodiaquine vs. artesunate-meflo-
quine; artesunate-amodiaquine vs. Am-SP; artesunate-
mefloquine vs. Am-SP)(Table 3).
Figure 1 shows that parasitic clearance on days 1 and 2
was slower with Am-SP compared with combinations
containing an artemisinin derivative (p < 0.0001).
All the strains responsible for clinical or parasitological
failure between days 21 and 28 were compared with the
strains collected on day 0 by PCR using the marker MSP 1.
Differences in strains were assessed on agarose gels using
the specific markers MAD 20, K1 and RO 33. This compar-
ison of strains with genetic markers before and after 'clin-
ical failure' resulted in a correction of the results. No case
of recurrence was observed after treatment with artesu-
nate-amodiaquine, artesunate-mefloquine and Am-SP
and 100% of clinical 'failures' were shown to be the result
of re-infection. In contrast, the level of re-infection with
artemether-lumefantrine (four-doses) was 84% (20/24)
(Figure 2). Ninety-five percent of cases of clinical failure
occurred in Kaolack. After correction for PCR results, a
comparative analysis of the different combinations dem-
onstrated that the difference between artemether-lume-
fantrine (four-doses) and the other combinations was no
longer statistically significant (Table 4).
When gametocytaemia was investigated, a reduction in
gametocyte carriage was observed from day 3 for combi-
nations including an artemisinin derivative, which acts
against this parasitic stage. For Am-SP, however, an
increase in number of patients carrying gametocytes was
observed between days 0 and 7 (Table 5). From day 14, no
gametocytes could be detected for any drug combination
with the exception of artemether-lumefantrine (six-doses)
(3%). By days 21 and 28, no patient had detectable game-
tocytes (Table 5).








(four doses) N = 140
Artemether-lumefantrine 





Parasitological failure, day14 0% 0% 0% 0% 0%
Clinical failure, day14 (n) 0% 0% 0.7% (1) 0% 0%
ACPR, day 14 100% 100% 99.3% 0% 100%
Gametocyte carriage, day 14 0% 0% 0% 3% 0%
Parasitological failure, day 21 0% 0% 0% 0% 0%
Clinical failure, day 21 (n) 1.4% (5) 0.7% (1) 3.6% (5) 0% 0.6% (1)
ACPR, day 21 98.6% 99.3% 96.4% 0% 99.4%
Gametocyte carriage, day 21 0% 0% 0% 0% 0%
Parasitological failure, day 28 (n) 0.8% (3) 0% 1.4% (2) 0% 0%
Clinical failure, day 28 (n) 0.3% (1) 1.4% (2) 11.4% (16) 0% 0.6% (1)
ACPR, day 28 97.5% 97.9% 82.8% 0% 98.7%
Gametocyte carriage, day 28 0% 0% 0% 0% 0%
ACPR, day 28 after PCR 100% 100% 96.4% 100% 100%
ACPR, day 42 (30% of patients) 100% 100% 100% 100% 100%






(four-doses) N = 140
Artemether-
lumefantrine 
(six-doses) N = 149
Amodiaquine-sulphadoxine-
pyrimethamine N = 161
Mean age (yrs) 15 15 12 13 12
Range 1–75 2–65 2–63 2–60 2–51
Mean wt (kg) 36 37 32 35 37
Range 5–102 11–110 12–83 6–89
Mean Parasitaemia (parasites/μL) 39800 27000 22000 15398 27000
Hb < 12 g/dL 68.6% 62.5% 96.7% 68.6% 70.3%
SGOT > 30 UI/L 15.2% 0% 9.7% 17.1% 0%
SGPT > 35 UI/L 0% 0% 0% 2.8% 0%
Creatininemia > 14 mg/L 0% 0% 0% 30% 0%Malaria Journal 2007, 6:80 http://www.malariajournal.com/content/6/1/80
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Clinical and biological tolerance of treatment
The side-effects observed with each treatment combina-
tion were minor. These consisted mainly of mild gastral-
gia, dizziness, pruritus, asthenia and vomiting. These side-
effects all disappeared at the end of treatment and did not
require any specific therapy (Table 6). No serious side-
effect requiring premature termination of treatment was
observed.
No severe alterations in renal or hepatic function were
observed with any of the drug combinations under study.
The transaminase increases observed on day 14 did not
exceed 2.5 × normal values. Only two patients (one
treated with artesunate-amodiaquine and one in the arte-
mether-lumefantrine group) presented with a slight
increase in creatinine levels without any serious clinical
signs (Table 6).
Discussion
The results of this study demonstrated that each of the five
antimalarial drug regimens tested had good clinical and
parasitological efficacy. When the efficacy results were cor-
rected for PCR results, an ACPR of 100% was observed
with artesunate-amodiaquine, artesunate-mefloquine,
Parasitic clearance with the five antimalarial drug combinations Figure 1
Parasitic clearance with the five antimalarial drug combinations.











Overall efficacy 97.5% 97.9% 82.8% 100% 98.8%
Artesunate-amodiaquine 0 NS P < 0.001 NS NS
Artesunate-mefloquine 0 p < 0.001 NS NS
Artemether-lumefantrine (four doses) 0 p < 0.001 p = 0.001
Artemether-lumefantrine (six doses) 0N S
Amodiaquine-sulphadoxine-pyrimethamine 0
NS: not significant.Malaria Journal 2007, 6:80 http://www.malariajournal.com/content/6/1/80
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artemether-lumefantrine given as six doses, and Am-SP.
Only artemether-lumefantrine given as four doses was
associated with a failure rate of 3.6%. An initial study con-
ducted in Senegal [6], did not detect any case of failure
after 4 years revealing that four-dose artemether-lumefan-
trine seems to have progressively lost its efficacy. It should
be noted, however, that most cases of failure were
observed around Kaolack, which is an important crossing
point between adjacent countries (The Gambia, Guinea
and Mali.), with a well established practice of self-medica-
tion and a readily accessible alternative drug market. The
highest level of failure due to chloroquine in Senegal has
also been noted in this area.
In Asia, studies have demonstrated that in areas where
transmission is high and where the population has a high
level of immunity to malaria, a therapeutic approach
based on four doses of artemether-lumefantrine gave
good results. Nevertheless, in non-immune populations
(especially in south-east Asia) this therapeutic approach
was associated with a failure rate of approximately 20%.
This failure rate was reduced to less than 5% by using a
dosage schedule based on six doses [7]. The failure rate
with artemether-lumefantrine given as four doses [8,10]
forced us to change to a six-dose regimen which gave a
better efficacy in this study.
The excellent efficacy observed with artesunate-meflo-
quine at the present dosage, seems to demonstrate good
activity against the asexual form of the parasite. Neverthe-
less, under the endemic conditions in our region, trans-
mission levels also confer a degree of protection which
can act synergistically with a drug. No case of re-infection
was observed after a follow-up period of 42 days. It
Genotyping of resistant strains isolated from patients treated with the different antimalarial drug combinations Figure 2

















Table 4: Comparison of the efficacy of artemether-lumefantrine (four doses) with the other antimalarial drug combinations at day 28 
after correction for PCR results
Artesunate-mefloquine Artesunate-amodiaquine Artemether-lumefantrine (six doses) Amodiaquine-sulphadoxine-pyrimethamine
Artemether-lumefantrine 
(four doses)
100%/96.4% p = 0.0019 100%/96.4% p = 0.065 100%/96.4% p = 0.0606 100%/96.4% p = 0.0492Malaria Journal 2007, 6:80 http://www.malariajournal.com/content/6/1/80
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appears, therefore, that the strains of P. falciparum
encountered in this study were highly susceptible to
mefloquine despite the small dose used (15 mg/kg meflo-
quine). However, to prevent a reduction in parasite sus-
ceptibility, an increase in the dosage of mefloquine to 25
mg/kg was necessary, as shown previously in other studies
[9].
The combination of Am-SP is still effective in Senegal and
in central Africa [11], while in east Africa cases of resist-
ance have been demonstrated [1,3,12,14].
Since 2003, the Programme National de Lutte contre le
Paludisme du Sénégal (National Malaria Control Pro-
gramme) has used the Am-SP combination instead of
chloroquine as a temporary strategy in the treatment of
uncomplicated malaria. However, it is believed that the
widespread use of this combination in addition to the use
of SP alone in pregnant women together with population
movements is likely to lead to the appearance of therapeu-
tic resistance to these drugs. Indeed, a study carried out in
Senegal on molecular markers of resistance to SP has dem-
onstrated the presence of triple mutations for dhfr and
dhps [15].
The gametocidal effect of artemisinin derivatives against
gametocytes has been demonstrated in other studies [14]
and has been confirmed in the current study; no gameto-
cytaemia was detectable in patients treated with an artem-
isinin derivative from day 3. Only the combination of
Am-SP resulted in increased levels of gametocytes until
day 7.
Genotyping of resistant stains using MSP1 and the alleles
K1, RO 33 and MAD 20 enabled us to differentiate cases
of recurrence from new infections.
All drug combinations were well tolerated in this study.
Only minor adverse events were observed, as seen in other
studies [16,17] and these did not require premature termi-
nation of treatment or specific medical care. All adverse
events disappeared at the end of treatment and no serious
adverse event was observed.
Similarly, clinical and biological tolerability was good for
all drug combinations. No unexpected adverse events
were encountered and all disappeared at the end of treat-
ment. No serious adverse event requiring premature ter-
mination of treatment was observed. However, it is












Anemia (Hb < 12) 0 35/51 15/24 30/31 24/35 19/27
68.6% 62.5% 96.7% 68.6% 70.3%
14 40/51 17/24 20/31 24/35 21/27
80.4% 70.8% 64.5% 68.6% 77.7%
SGOT > 30 0 9/59 0/27 3/31 6/35 0/27
15.2% 0% 9.7% 17.1% 0%
14 16/59 8/27 8/31 04/35 10/31
27.1% 29.6% 25.9% 11.4% 32.2%
SGPT > 35 0 0/59 0/27 0/31 1/35 0/27
0% 0% 0% 2.8% 0%
14 3/58 3/27 4/31 1/35 2/31
5.1% 11.1% 13% 2.8% 6.4%
Creatininemia > 14 0 0/59 0/27 0/37 30% 0/27
0% 0% 0% 0%
14 3/58 2/27 1/37 9/35 2/31
5.1% 7.4% 2.8% 25.7% 6.4%
Table 5: Evolution of gametocyte carriage according to antimalarial drug treatment through the study period
Day 0 3 7 14 21 28
Artesunate-amodiaquine 0% 0% 0% 0% 0% 0%
Artesunate-mefloquine 0% 2% 0% 0% 0% 0%
Artemether-lumefantrine (four doses) 2% 2% 0% 0% 0% 0%
Artemether-lumefantrine (six doses) 3% 6% 6% 3% 0% 0%
Amodiaquine-sulphadoxine-pyrimethamine 3% 10% 12% 0% 0% 0%Malaria Journal 2007, 6:80 http://www.malariajournal.com/content/6/1/80
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important to carry out further pharmacovigilance studies
before these combinations are used more widely.
Artemisinin derivatives in combination with classical
antimalarial drugs, which are still effective as mono-
therapy, represent, therefore, the best options for the treat-
ment of malaria in situations where chloroquine
resistance exists. Possible hurdles to their use as treatment
strategies for uncomplicated malaria include their rela-
tively high cost and their availability in the context of a
high worldwide demand. Considerable commitment by
the pharmaceutical industry and increased participation
of international organizations are necessary to give the
population of these poor countries access to antimalarial
drug combinations based on artemisinin derivatives.
On the basis of these results, Senegal has modified its
approach to treatment of malaria since 2004 and has
adopted artesunate in combination with amodiaquine as
first-line therapy for the management of uncomplicated
malaria. However, a regular monitoring of this strategy is
essential because therapeutic failures were documented in
the south of Senegal [18].
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